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Digitalizationa b s t r a c t
Materials and manufacturing processes share a common purpose of enabling the pharmaceutical product
to perform as intended. This review on the role of polymeric materials in additive manufacturing of oral
dosage forms, focuses on the interface between the polymer and key stages of the additive manufacturing
process, which determine printability. By systematically clarifying and comparing polymer functional
roles and properties for a variety of AM technologies, together with current and emerging techniques
to characterize these properties, suggestions are provided to stimulate the use of readily available and
sometimes underutilized pharmaceutical polymers in additive manufacturing. We point to emerging
characterization techniques and digital tools, which can be harnessed to manage existing trade-offs
between the role of polymers in printer compatibility versus product performance. In a rapidly evolving
technological space, this serves to trigger the continued development of 3D printers to suit a broader
variety of polymers for widespread applications of pharmaceutical additive manufacturing.
 2021 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
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Additive manufacturing (AM), colloquially termed 3D printing,
encompasses a range of manufacturing technologies which are
characterized by layer-by-layer material deposition to fabricate
three-dimensional objects under digital control based on a
computer-aided design (CAD) model or scan [1–10]. Beyond rapid
prototyping, its utility over conventional pharmaceutical product
fabrication has been mainly attributed to its high design freedom,
which enables customization, its ability to form parts with com-
plex internal and external geometries, and its ability to rapidly
modify parts without the need for retooling [2,3,11,12]. Realizing
these advantages relies on an intricate interplay between the
design, the process parameters, the tooling, and the materials to
be processed. A variety of materials have been used in AM in
healthcare applications, including metals, ceramics, and polymers,
with the latter being of primary relevance to pharmaceutical
dosage forms [13,14].
The oral route of administration, especially the delivery of solid
oral dosage forms, remains the predominant route of administra-
tion for pharmaceutical products for several reasons including its
convenience, ease of handling and portability, suitability for self-
administration, and so forth. Therefore, this review will focus on
the role of polymeric materials in AM of oral pharmaceutical
dosage forms, together with appropriate characterization methods
for understanding and optimizing AM processibility and product
performance. Several reviews of polymers in AM have emerged
recently, which specify pharmaceutical applications [15–23]. Com-
prehensive summaries and exemplification of polymers in AM can
be found therein, with exhaustive lists of polymer types and char-
acterization techniques used in AM. However, key questions2
remain regarding the extent of utilization of pharmaceutically
approved polymers across various AM technologies, i.e., which
polymers are not yet used and why? In addition, how do polymer
properties relevant to different stages of the AM process, e.g. feed-
ing, deposition, and adhesion, compare across the various AM tech-
nologies used in pharmaceutical research? Lastly, are the
characterization techniques already used to assess product perfor-
mance equally suited to assess printability? To answer these ques-
tions, this review primarily highlights the interface between the
polymer and key stages of the AM process that determine print-
ability. Here, printability involves the capability to generate repro-
ducible printed objects according to the specifications of the
intended design [24]. By systematically clarifying and comparing
selected polymer functional roles and properties for a variety of
AM technologies, together with the means to characterize these
properties, suggestions are provided to stimulate the use of
underutilized but already available pharmaceutical polymers and
emerging analytical tools to guide the evolution of AM for pharma-
ceutical applications. For the purposes of this review, process
stages influencing printability are limited from process input to
process output. Post-processing steps that can further enhance
product quality or correct or mask print defects are considered
out of scope.
Beyond this introduction in Section 1, Section 2 describes the
various roles polymers need to exhibit to facilitate printability
for different AM technologies. Section 3 highlights some trade-
offs faced when balancing printability and product performance,
with specific examples involving achieving the desired solid state
and facilitating drug delivery. Section 4 summarizes current and
emerging polymer characterization techniques as they relate to
understanding, optimizing and monitoring printability of poly-
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expert opinion provided in Section 6, where the authors offer per-
spective to guide further progress in this rapidly evolving field.2. The role of polymers in printability
According to ISO/ASTM 52900, there are 7 process categories of
additive manufacturing, each with several specific process exam-
ples [25]. These include material extrusion (e.g. fused deposition
modelling (FDM), pressure-assisted micro-syringe (PAM) printing,
melt extrusion deposition), material jetting (e.g. drop-on-demand
(DoD) printing on a substrate), binder jetting (e.g. drop-on-
powder (DoP) printing), powder bed fusion (e.g. selective laser sin-
tering (SLS)), VAT polymerization (e.g. stereolithography (SLA),
digital light processing (DLP), continuous liquid interface produc-
tion (CLIP)), directed energy deposition (e.g. laser metal deposi-
tion), and sheet lamination (e.g. laminated object manufacture).
Except for the latter two, these additive manufacturing process cat-
egories have been employed for pharmaceutical applications in the
academic research setting. Furthermore, in 2015, the antiepileptic
Spritam (levetiracetam) from Aprecia Pharmaceuticals, fabricated
by a binder jetting process patented as ZipDose technology,
gained market approval from the FDA [26]. More recently, in
2021, T19 from Triastek, fabricated by a material extrusion process
called melt extrusion deposition, gained FDA clearance as an inves-
tigational new drug for rheumatoid arthritis [27,28]. For detailed
descriptions of all operations for all AM technologies, which have
different working mechanisms, the reader is referred to dedicated
reviews on each AM technology [29–34]. In this section, we instead
compare AM technologies across a few key process stages, namely
feeding, deposition, and adhesion. These three process stages are
not only highlighted because they are common to several (but
not all) pharmaceutical AM technologies but also because they
are key determinants of product quality upon 3D printing. Fig. 1
summarizes key polymer functions for common stages of the AM
process, accompanied by the specific polymer properties that are
required to elicit these functions. In the discussions of each of these
important process steps in Sections 2.1-2.4, we describe some ofFig. 1. A deconstructed AM process for selected AM technologies showing examples of ke
SLS = selective laser sintering, DoD = drop-on-demand printing, PAM = pressure-assiste
3
the key polymer functions required for printability, together with
examples of currently used polymers. In Section 2.5. we identify
some under-utilized pharmaceutically approved polymers which
are still under-utilized in AM despite exhibiting potentially suit-
able properties for printability.
To select appropriate polymers for oral dosage forms fabricated
by AM and critically examine their use in different AM technolo-
gies, the well-established Handbook of Pharmaceutical Excipients
served as an important tool in this review [35], from which around
70 pharmaceutically approved polymers were identified. By subse-
quently inserting their common names and CAS numbers into
SciFinder ( 2021 American Chemical Society), a list of search hits
was generated. These were filtered for relevant examples of origi-
nal research articles from the different AM technologies with prod-
ucts that could be orally administered. Polymers that are
commonly used for biomedical purposes, such as agarose,
polyetheretherketone, and polyurethanes, were excluded. More
than 30 polymers were identified for use in pharmaceutical AM
of oral dosage forms (Table 1). The reader is referred to the refer-
ences listed within Table 1 for specific details on the exact func-
tionality of each polymer and the compositions of the specific
printed formulations.2.1. Feeding
Feeding into the nozzle is a critical step towards printability.
This function is discussed with respect to all process categories
mentioned above, except for powder bed fusion and VAT polymer-
ization, which lack nozzle-based working principles. Different AM
processes are compatible with different forms of feedstock, giving
rise to different material properties of relevance (Fig. 1).
During FDM, a melt extruded polymeric filament feedstock is
fed through the nozzle via rotating drive gears. The feeding of
the filament through the drive gears of the FDM machinery gener-
ates the pressure required to initiate deposition of high-viscosity
melts [73,86]. The FDM feeding mechanism is therefore not only
controlled by the AM machinery but also by the filament itself.
The implication of this is that selection of the filament compositiony polymer properties of relevance at each stage. FDM = fused deposition modelling,
d micro-syringe, DoP = drop-on-powder printing, SLA = stereolithography.
Table 1
List of pharmaceutically approved polymers with referenced examples indicating their oral drug delivery applications in various AM technologies. FDM = fused deposition
modelling, PAM = pressure-assisted micro-syringe, SLS = selective laser sintering, DoP = drop-on-powder printing, DoD = drop-on-demand printing.
AM Technology




FDM PAM SLS DoP DoD
carbomer [36]
carboxymethylcellulose sodium (Na-CMC) [37]
cellulose acetate [38] [39]
cellulose acetate phthalate [40]
cellulose (microcrystalline cellulose, MCC) [36,41] [42] [43–45]
copovidone (Kollidon VA64) [46–50] [42,51]
croscarmellose sodium [37,52]
crospovidone [36]
ethylcellulose (EC) [47,49] [53,54] [55–57]
gelatin [41] [58]
hydroxyethyl cellulose (HEC) [59] [60]
hydroxypropyl cellulose (HPC) [48,49,59,61–63]
hypromellose (HPMC) [46,47] [39,41,52,64] [51] [55–57] [65–67]
hypromellose acetate succinate (HPMCAS) [68]
hypromellose phthalate [40,69]
maltodextrin [48] [60,70] [71]
pectin [70]
poloxamer (Pluronic) [72] [67]
polycaprolactone (PCL) [40,73] [74] [75]
polyethylene glycol (PEG) [40,47–49,63,76] [39] [45,77] [66,67]
polyethylene oxide (PEO) [59,62,63,76] [75]
polylactic acid (PLA) [50,78]
polymethacrylates (Eudragit) [40,47] [79] [43,44,55]




polyvinyl alcohol (PVA) [38,47,49,50,76,78,81,82]
polyvinyl alcohol/polyethylene glycol graft copolymer (Kollicoat IR) [48] [53,79]
polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft
co-polymer (Soluplus)
[46,47,76] [77]
povidone (Kollidon PVP) [38,40,47,83] [39,52] [43–45,55,57,71] [80]
pullulan [84]
sodium starch glycolate [39]
starch [85]
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(e.g. in terms of appropriate and accurate dose, drug release, stabil-
ity, and so forth) and enable the filament to facilitate printability
by acting as a piston during FDM. In addition to facilitating print-
ability during the feeding step, the polymers listed in Table 1 under
the FDM category have additional functions in the formulations, for
example, as drug carriers, compartment builders, or plasticizers. In
the following paragraph, material properties exclusively for print-
ability during the feeding stage will be addressed. Material proper-
ties for product performance will be introduced in Section 3 to
elucidate the major balancing act between printability and product
performance that needs to be solved to successfully integrate AM
technologies into the pharmaceutical space.
The success of the feeding step during FDM is primarily gov-
erned by the filament mechanical properties (Fig. 1) and includes
measures of stiffness, flexibility, tensile strength, Young’s modulus,
toughness, yield strength, and ductility [29,73,87]. Melt-extruded
filaments for pharmaceutical FDM are typically solid dispersions
of the drug in a thermoplastic polymeric carrier (Table 1), with
potential inclusion of additional excipients in the formulation.
These excipients include polymeric additives acting as plasticizers
to promote printability, such as PEG and Pluronic [48,88]. Alter-
natively, drug-free polymeric filaments, containing PVA or PLA,
for example, have been used to generate capsules or alternative
compartmentalized product architectures [78,89]. In both cases,
filament mechanical properties are dictated in part by the polymer
type and content, particularly when the polymer(s) forms a large
fraction of the composition. If the resulting filament is too brittle,
it will break under the force of the drive gears. If the filament is4
too soft, it will deform between the drive gears and fail to act as
a piston to drive deposition from the nozzle. In addition to
mechanical properties, material thermal properties are also highly
relevant for FDM feeding. Firstly, thermal properties and mechan-
ical properties are correlated. The thermal properties of relevance
for the polymer include its glass transition temperature (Tg), melt-
ing temperature (Tm), thermal degradation temperature (Tdeg) and
heat distribution [15,76,90,91]. Since polymers could be semi-
crystalline, the softening of polymers could occur at any point
between the Tg and Tm and does not necessarily require melting
to occur. Plasticizing the polymer with other excipients, plasticiz-
ing drugs, or moisture, leads to depression of Tg, which will alter
both the thermal and mechanical behaviour. The inclusion of poly-
mers which have too low a Tg or Tm, like gelatin (Tm < 35 C) [92],
will be unsuitable for feeding as an FDM feedstock, when included
in high proportions as carriers, since this often results in filaments
which are too soft for successful feeding. This challenge of filament
feeding is further compounded with natural polymers, which exhi-
bit an inherent variation of properties. For example, the Tg of shel-
lac has been reported to vary between 33 C and 52 C [93].
Thermal properties and rheological properties are inter-related
and together influence feeding. The primary rheological property
of interest is viscosity [94,95]. High-viscosity melts at the nozzle
end require tougher filaments to force it through the nozzle orifice
at a given temperature. Low-viscosity melts at the nozzle end
could result in failure of the piston mechanism if it results in pool-
ing of molten material in the heating chamber above the nozzle.
Using polymers which have sufficiently wide thermal processing
windows between Tg or Tm and Tdeg can help in optimizing the vis-
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viscosity of the polymer melt can also be controlled by using the
same type of polymer at a different molecular weight for optimiz-
ing feeding. Several viscosity grades are available for PEO and
HPMCAS for this purpose. An important consideration is that the
short exposure time to heat during FDM feeding means that ther-
mal gradients in polymer-based materials are expected to play a
key role in obtaining the desired melt viscosity and therefore print-
ability during the feeding step.
To circumvent the reliance on filaments with optimal mechan-
ical properties during FDM feeding, an alternative but related tech-
nique has been introduced, namely direct powder extrusion (DPE)
[96,97], also trademarked as melt extrusion deposition [28]. As the
name suggests, this process allows direct feeding of raw materials
or physical mixtures into a built-in extruder upstream of the prin-
ter nozzle. This process solves a critical and challenging material
property encountered during FDM, specifically during the feeding
stage of printing. In doing so, the range of processible materials
is potentially expanded for DPE compared to FDM. In the authors’
collective view, such an evolution of AM technologies towards
enhanced material diversity will be a key deciding factor in the
extent of applicability of AM to future pharmaceutical products.
The development of DPE did not merely involve selection of an
alternative existing filament-free AM technology but rather
focused on the specific stage and specific material property that
required improvement in a conventional FDM process. The mate-
rial thermal properties and rheological properties discussed above
remain relevant to the working principle of DPE. However, due to
the use of raw materials or physical mixtures which do not require
pre-processing and are in powder form when exposed to the rela-
tively large heated surface and high shear of the built-in extruder,
thermal gradients that exist with melt-extruded filaments and
short residence times during FDM become a far less critical factor
in determining printability in the feeding stage of DPE. Notably,
melt-based DoD technologies offer a similar benefit for printability
during feeding, especially when powder feedstocks are used. How-
ever, when pre-extruded and pelletized feedstocks are favoured for
melt-based DoD, DPE offers greater process efficiency without its
reliance on a separate upstream pre-processing unit operation.
Feeding of solvents instead of melts through a nozzle may occur
for certain AM technologies for example, PAM and solvent-based
DoD. Although PAM is often used interchangeably with semisolid
extrusion 3D printing (SSE) in the pharmaceutical AM literature
[30,84,98], there are also instances where SSE is described as a
broader conceptual term encompassing different material extru-
sion mechanisms, for example, pneumatic extrusion, mechanical
extrusion, and solenoid extrusion [99]. For this review, we exem-
plify the SSE category with PAM to represent the deposition of gels
and pastes typically through non-heated nozzles (although heat
could optionally be introduced). In addition to FDM mentioned
above, both PAM and solvent-based DoD require an extra process
step (i.e., dissolving and/or dispersing) before feeding into the
AM technology. For solvent-based DoD, a drop generator is located
above the orifice as part of the machinery, which is connected to a
reservoir of ink via a channel that restricts flow and controls the
refilling process. For the refilling process to function optimally, vis-
cosity and surface tension are important attributes [100]. Polymers
may be added to the solution to modify each of these properties,
however, both surface tension and viscosity are typically opti-
mized with priority on controlling drop dynamics during deposi-
tion and not the feeding. These properties and the role of the
polymer in modifying them for solvent-based DoD printing as well
as PAM will therefore be addressed in more detail in Section 2.2.
Similar to DoD, the feedstock in PAM should have an appropriate
viscosity to arrive at the nozzle orifice and the generation of this
feedstock also requires an extra process step before PAM.5
2.2. Deposition
One of the most crucial polymer functions that governs print-
ability for several AM techniques is deposition from a nozzle.
Deposition may occur through a heated or non-heated nozzle, each
of which requires different polymer properties (Fig. 1).
Deposition through a heated nozzle occurs during FDM, melt
extrusion deposition, and melt-based DoD printing on a substrate.
These AM technologies require polymers to be thermoplastic, as
mentioned in Section 2.1. Therefore, thermal and rheological prop-
erties are relevant for deposition through the heated nozzle. FDM
deposition or melt extrusion deposition, which involve continuous
extrusion from the heated nozzle, can occur above the Tg or above
the Tm of the formulation. Notably, all melt-based AM technologies
with continuous extrusion from the nozzle may give rise to die
swell [101]. Melt-based DoD, however, is characterized by the
deposition of droplets and therefore requires printing above the
Tm to provide an appropriate melt viscosity for droplet formation
and deposition [66,67].
Using polymers with a high Tg in AM technologies with heated
nozzles typically requires decreasing of the Tg, which can be
obtained by mixing with excipients which have more suitable ther-
moplastic properties [102]. A low Tg excipient can give rise to plas-
ticization if it is compatible with and mixed well with a polymeric
carrier with a higher Tg. These plasticizers may either be small
molecules or polymers. One example of a commonly used poly-
meric plasticizer in AM applications is PEG [76,103]. Polymers with
too low Tg that are processed alone without antiplasticization pro-
vided by other components in the formulation, may result in
uncontrolled and inaccurate deposition from heated nozzles, due
to lowmelt viscosities at the processing temperatures encountered
during melt-based AM printing. An example of a polymer with a
low Tg in the presence of moisture is polydextrose, which exhibits
a Tg below room temperature at 50% relative humidity [104],
potentially too low to achieve appropriate rheological properties
on its own for processing through heated nozzles. In contrast, cal-
cium alginate or barium alginate exhibit an increased Tg as the
amount of ions increases and as the extent of cross-linking
between the divalent cations and the polymer chains increases
[105]. This may require a processing temperature which exceeds
that which is possible with the heated nozzles in AM. This phe-
nomenon is also observed for covalent cross-linked car-
boxymethylcellulose sodium [106]. Other polymers which have a
high Tg, for example, methylcellulose, polymethyl vinyl ether/-
maleic anhydride, and zein (Tg > 150 C) [35], may also hinder
deposition when used alone, necessitating careful selection of plas-
ticizers [107]. The potentially plasticizing effects of added of drugs
and exposure to moisture also needs to be taken into account when
optimizing the printability of the polymer formulation in heat-
based AM.
For deposition through non-heated nozzles, polymer properties
of interest are governed by whether the deposition process is
extrusion-based or jetting-based. An example of the former is
SSE via PAM. The polymers used in PAM (Table 1) have different
functions in the formulations, for example providing appropriate
rheological properties, providing the required solids content to
the formulation, and achieving the desired final product perfor-
mance. Rheological properties, particularly viscosity, yield point
and yield stress under shear and pressure, are crucial [5]. The yield
point refers to the stress required to initiate flow. For materials
which have a high yield point, the deposition of the material will
be limited by the maximum pressure applied by the printer and
the maximum shear forces tolerated by the material. For materials
which have too low a yield point, there could be uncontrolled leak-
age of material from the nozzle under the influence of gravity. The
importance of rheology for PAM is demonstrated by the fact that
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(viscosity-increasing) agents (see Table 1, e.g. carbomer, HEC,
HPMC and PVP). The semi-solid nature of formulations for PAM
mean that polymer concentrations are often above the overlap
concentration. However, in PAM, since the content of gel-forming
polymer can be quite low, the formulations often include solid
excipients that serve to increase the solid content of the dried
dosage forms in order to shape and strengthen the structure or
provide specific product properties or performance. These are poly-
mers that are traditionally used in oral tablets or capsules, like
diluents (Table 1, MCC) and disintegrants (Table 1, MCC, sodium
starch glycolate, carboxymethylcellulose sodium). Since the solids
content will influence the rheological properties of the paste, not
only should it contribute to the final product structural integrity
but it should also be optimized to ensure appropriate deposition.
With solvent-based jetting processes, surface tension and vis-
cosity are the primary formulation properties of interest, which
govern drop dynamics. Although the main carriers in these pro-
cesses are solvents, polymers may be included to obtain the
required properties [108]. Viscosity and surface tension act
together to contribute to printability during DoD printing. For
deposition to occur, sufficient pressure should be applied above
the nozzle to overcome the viscous forces and surface tension of
the liquid and deposit the droplet [108]. This pressure is supplied
by piezoelectric, electrostatic, or thermal actuators [5]. Upon ejec-
tion of a liquid jet from the nozzle, the surface tension is a major
factor responsible for droplet formation [109,110]. Sufficiently
low surface tensions are required for droplet formation. At the
same time, sufficiently high surface tensions are required to pre-
vent leaking from the nozzle when deposition is not occurring
[100,108,110]. An optimal surface tension working range has been
reported to lie between 30 and 70 mN/m [8,12,111] and the opti-
mal viscosity should be between 2 and 20 mPas, typically around
10 mPas [109], which is low enough to facilitate ejection from
the nozzle and high enough to discourage the formation of satellite
droplets [108,109]. The reader is referred to Alomari et al. [100],
where surface tensions and viscosities for a range of printed for-
mulations are tabulated. The inclusion of polymers in the formula-
tion could contribute to achieving optimal surface tensions and
viscosities of printing inks for successful deposition [109]. The
most commonly used polymeric viscosity modifier for DoD tech-
nologies is PEG [100]. Examples of polymers that have been used
for jetting techniques with the aim to control both surface tension
and viscosity are amphiphilic cellulose derivatives like the com-
monly used HPMC, whereas others like HEC and HPC have the
potential to be utilized more in future (Table 1). A further example
of a polymer commonly used to control surface tension is the
polymer-based surfactant, Tween, whereas other surfactants like
Pluronic and polyoxyethylene stearates have not been as fre-
quently used for jetting technologies thus far. The same properties
apply for melt-based DoD printing with the added consideration
that, where molten polymers are the primary carrier, viscosity
and surface tension are temperature-dependent [67]. Although
thermoplastic properties are specific to deposition from heat-
based extrusion-based AM and surface tension is specific to the jet-
ting processes, the above discussion reveals that viscosity plays a
central role as a material property defining the success of deposi-
tion regardless of the distinct working principles of the nozzle-
based AM technologies.
SLS, a powder bed fusion process, is an example of non-nozzle-
based deposition, where polymer powder is fed from a reservoir to
the build-plate using a sled. Therefore, polymer powder flow prop-
erties, governed in part by powder particle morphology and parti-
cle size distribution, are of primary importance [112].6
2.3. Adhesion
Adhesion to the build-plate, an alternative substrate, or the pre-
ceding deposited layer, is another crucial polymer function that
constitutes printability (Fig. 1). During FDM, adhesion to the build
plate and previous printed layer has been related to surface ten-
sion, viscosity, and mechanical properties like brittleness [87], all
of which can be modulated through polymer selection or the addi-
tion of plasticizers to formulations. Polymers which do not neces-
sarily need to be included in the formulation can be specifically
selected to act as a support structure, for example a raft, to
improve first-layer adhesion and prevent warping. Such support
structures can be removed once the pharmaceutical product has
been constructed, as post-processing step [87]. Polymers which
exhibit good adhesion to several other polymers are expected to
be highly beneficial in encouraging first-layer adhesion of a variety
of AM formulations. Specifically, for layer-to-layer adhesion, a
semi-molten state with an appropriate relaxation time to allow
the polymer to diffuse across the interface between deposited lay-
ers, is most desirable [4], making thermal properties an additional
contributor to adhesion. At temperatures slightly above Tg, the
polymer may exhibit a degree of stickiness, which can promote
adhesion. Although a sufficiently low viscosity is required for
spreading and adhesion onto the previous layer, viscosity should
not be so low as to result in a flowing liquid or excessive spreading
or coalescence of layers that would hinder the geometric accuracy
of the printed construct. Notably, rapid cooling is also required
after deposition of each layer to prevent layer to layer coalescence.
For solvent-based processes, like solvent-based DoD printing,
the surface tension and viscosity of the formulation may be opti-
mized through the inclusion of appropriate polymers to encourage
adhesion without unwanted coalescence of droplets [108]. An
interesting application of polymers in solvent-based DoD printing
occurs during the layering of droplets, for example, to achieve
the desired drug loading. Since droplets are expected to spread dif-
ferently on the substrate versus on the previous deposited layer,
drug-free polymeric layers could be deposited in between each
drug-containing layer and on the substrate to improve or obtain
consistent and predictable adhesion [108]. The polymers used in
the jetting techniques can be classified as (i) polymers included
in the printing ink or droplets, where they function in controlling
the rheological properties and surface tension or (ii) polymers that
serve as the powder or substrate onto which the droplets are
deposited. Both play a role in achieving optimum adhesion. To
some extent, this resembles PAM, where the initial dry raw mate-
rial is wetted by a liquid commonly containing polymer binders,
which not only contributes to the final product structural charac-
teristics but is also key to promoting interlayer adhesion. Upon
scrutinizing Table 1, it is therefore unsurprising that a few poly-
mers like HPMC, PEG, PVP, and MCC are frequently used in both
PAM and jetting processes.
During selective laser sintering, powder particle adhesion is
central to its working principle and requires polymer stability
against high laser temperatures, appropriate thermomechanical
properties, and low melt surface tension to encourage powder par-
ticle coalescence [13]. Successful layer to layer adhesion during SLS
without the formation of unwanted voids relies on having an
appropriate particle morphology and narrow particle size distribu-
tion to provide a homogeneous powder bed prior to sintering.
2.4. Polymerization
Polymerization can occur as a post-printing solidification step
after the 3D object is generated, for example in material jetting
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[99,113]. Appropriate cross-linkable materials are required for
the chosen cross-linking mechanism. This could involve pho-
topolymerization or thermal, ionic, or pH-induced cross-linking
[113]. Solidification by photopolymerization as a post-processing
step is currently encountered primarily in biomedical applications.
Polymerization may also be an inherent part of generating the
three-dimensional object, as is the case with VAT polymerization
(e.g. SLA and DLP). Here, spatially controlled photopolymerization
of a liquid polymer resin is initiated under computer control to
generate a solid three-dimensional object [33]. The polymer needs
to be a photopolymer which undergoes polymerization with the
aid of a photoinitiator to form a cross-linked polymeric network,
which may entrap the drug during formation of the network or
allow for subsequent drug loading [33,114–116]. Unlike other
additive manufacturing processes, where the process inputs or
feedstocks are polymers, the liquid resins in VAT polymerization
consist of multi-functional monomers, typically based on
methacrylate or acrylic esters [33]. Both SLA and DLP have been
used for drug delivery research [33]. SLA has been used specifically
in oral drug delivery research with photopolymerizable resins con-
taining primarily polyethylene glycol diacrylate 700 (PEGDA 700)
or N-vinyl-pyrrolidone as the reactive oligomer or monomer and
polyethylene glycol 300 (PEG 300) as the liquid non-reactive filler
[114–117], together with the drug and photoinitiator. The first
example of SLA for oral drug delivery involved the fabrication of
paracetamol and 4-aminosalicylic acid tablets using PEGDA and
PEG 300 [115]. More recently, mucoadhesive microresevoirs for
oral drug delivery and enhanced mucoadhesion have also been
demonstrated using SLA [118]. Although applications of VAT poly-
merization for oral drug delivery have been demonstrated in
research, so far, most utilized photopolymers and the monomersFig. 2. Summary of generalized steps and typical polymer properties for the AM techn
PAM = pressure-assisted micro-syringe, c) SLS = selective laser sintering, d) DoP = drop-
based DoD. Tg = glass transition temperature, Tm = melting temperature, Tdeg = degrada
7
they are generated from are not generally recognized as safe or
pharmaceutically approved. Indeed, Table 1 reveals that out of
the 5 process categories of pharmaceutical AM, the main users of
approved excipients are material extrusion, powder bed fusion,
binder jetting and material jetting. Therefore, VAT polymerization
is addressed in a limited manner henceforth in this review.
So far, this section has highlighted key polymer functions which
aid printability and the polymer properties they require, with
examples of specific polymers utilized that offer these properties
for various AM processes. Since different AM processes have differ-
ent specific requirements for printability, no single AM technology
can process all pharmaceutically available polymers. Notably, the
polymer properties required for printability are dependent on
whether the AM technology is melt-based or solvent-based, with
added considerations for whether they are based on continuous
extrusion or jetting. Despite their unique working mechanisms,
this may allow a degree of overlap in the polymers which are suit-
able for different process stages for different AM technologies. In a
rapidly evolving technological space, such an insight should trigger
the development of printers that support hybrid printing mecha-
nism to suit a broader variety of polymers and potentially broader
pharmaceutical applicability. The upcoming section will shed light
on an identified research gap, where pharmaceutically approved
polymers are pointed out, which demonstrate suitable properties
for printability according to Sections 2.1 to 2.4 but are still not
commonly utilized in specific pharmaceutical AM processes.2.5. Pharmaceutically approved polymers underutilized in AM
Fig. 2 summarizes critical polymer functions for each stage of
printing for each AM technology. By scrutinizing the three centralologies further discussed in this review, a) FDM = fused deposition modelling, b)
on-powder printing, e) solvent-based DoD = drop-on-demand printing and f) melt-
tion temperature.
Fig. 2 (continued)
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bring to light the similarities and differences between required
polymer properties for different processes. This serves as a basis
for suggesting appropriateness of underutilized pharmaceutically
approved polymers for specific AM technologies. In doing so, we
hope to stimulate scientists working in the pharmaceutical AM
arena to explore well-known polymers beyond their current use.
All melt-based AM processes share polymer requirements when
it comes to thermal properties andmelt-rheology, therefore several
of the polymers already used in FDM (Table 1) are also appropriate
for melt-based DoD or even SLS. Most polymer examples used in
FDM are traditionally intended for coating or film-forming applica-
tions [35] because these functions also require thermoplasticity.
These include polyvinyl alcohol, polymethacrylates, cellulose acet-
ate, hydroxypropyl methylcellulose, and copovidone, to name a few
(Table 1). There are additional pharmaceutical polymers like ali-
phatic esters and povidone, which are not classified as coating
agents or film formers but nevertheless have suitable Tg and/or
Tm for deposition through heated nozzles. On the other hand, not
all film formers are suitable on their own for deposition through
heated nozzles due to thermoplastic properties which may be
incompatible with the typical operating temperature ranges of
heated nozzles in AM, for example, too high Tg. The process window
for melt-based AM techniques should be below Tdeg but above Tg or
Tm. Excessively high Tg narrows the processing window, potentially
compromising the optimization of printability. A high Tg relative to
Tdeg is a common feature for dry non-substituted polysaccharides,
including starch, cellulose, xanthan, carrageenan, and so forth,
making their poor thermoplastic properties unsuitable for melt-8
based AM. Although Table 1 reveals one exception to the exclusion
of non-substituted polysaccharides, namely, maltodextrin, the
reported content of maltodextrin in the cited study was below
15%, where it functioned as a pore forming agent [48], not as the
primary polymeric carrier. Unlike the non-substituted polysaccha-
rides, many substituted polysaccharides, like CA, HPMC, EC, HPC,
and so forth, do indeed exhibit appropriate thermoplastic proper-
ties to function as the primary polymeric carrier. Substituted
polysaccharides exhibit a lower Tg than unsubstituted polysaccha-
rides and maintain their Tdeg due to the fact that hydrogen bonding
between the hydroxyl groups in the polysaccharides are reduced to
some extent by the addition of substituents [119,120]. Thus, the
type of substituent and number of substituents largely impact the
thermoplastic properties and could play a key role in widening
thermal processing windows for melt-based AM.
Table 2 summarizes underutilized polymers together with
examples of their functional properties and suggestions of which
AM category they may be useful for. Two potential thermoplastic
drug carriers or compartment builders that may show promise
for FDM applications are ethylene vinyl acetate (Tm between
75 C and 102 C) and polyvinyl acetate phthalate (Tg approxi-
mately 42 C) [35]. It is well-known that PEG and the amphiphilic
surfactant, Pluronic, referenced in Table 1, can be used as plasti-
cizers. It is feasible that an under-utilized polymer class for melt-
based AM, the ‘‘polymer-like” surfactants, with their strong amphi-
philic character, may also find similar uses in melt-based AM.
Examples include sorbitan fatty acid esters, polyoxylglycerides,
polyoxyethylene sorbitan fatty acid esters, and polyoxyethylene
stearates.
Table 2
Summary of examples of pharmaceutically approved polymers that are not commonly used in oral formulations produced by different AM technologies with suggestions of where
their properties might promote printability alongside their current functionalities. Functional categories are obtained from [35], except where specific references are cited.
Polymers and polymeric containing surfactants Melt-based AM technologies Solvent-based AM technologies
Thermoplastic
part
Additives Solvent part Dry part
Natural polymers






(low-substituted HPC, methylcellulose, hydroxyethylmethyl cellulose,









(ethylene vinyl acetate, polycarbophil, polyvinyl acetate phthalate,
polymethyl vinyl ether/maleic anhydride, dimethicone)
Carrier [124] Film substrate [123], stabilizer of
solid dispersions [124], anti-foam-
ing agent
Polymeric surfactants
(polyoxyethylene alkyl ethers, sorbitan fatty acid esters,





Solubilizing agent, wetting agent
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ties can be found between SLS and melt-based AM techniques
which feed polymers via a nozzle. Polymers like Kollidon VA64,
EC, HPMC, PEG, and Kollicoat IR are commonly used in both AM
technologies, first in FDM and later in SLS. Perhaps, in future, the
wide range of thermoplastic polymers already used in FDM, includ-
ing PEO, PVP and PVA, to name a few, may continue this trend to
find increased use in SLS.
Solvent-based AM processes, such as PAM, solvent-based DoD,
and DoP, also exhibit similarities in the types of polymers that
are useful. The largest category of polymers, identified from the
Handbook of Pharmaceutical Excipients, which are not commonly
used in AM for oral formulations is the water-soluble polysaccha-
rides (e.g. guar gum, carrageenan, and alginic acid). Their tradi-
tional uses outside of AM include their functions as stabilizing
agents for suspensions, emulsifiers, and viscosity-controlling
agents [35]. The second largest category is the cellulose deriva-
tives, including low-substituted HPC, carboxymethylcellulose cal-
cium, and hydroxyethylmethyl cellulose, which have been used
outside of AM as binding agent in tablets, emulsifying agents,
and coating agents, respectively, in conventionally manufactured
oral dosage forms [35]. In addition, the viscosity-increasing syn-
thetic polymers (polyvinyl alcohol, polymethacrylates) are useful
for PAM. All remaining aforementioned polymers are strong candi-
dates for increased use in both PAM and other solvent-based AM
processes. The natural polymers listed here are not typically
encountered with PAM for oral drug delivery, but could have
potential here, especially since some are already utilized in PAM
for biomedical applications [121,122]. A related exception is the
use of the polysaccharides, maltodextrin and pectin, to 3D print
chewable oral dosage forms containing isoleucine and additional
excipients using a modified gummy candy 3D printer, based on
SSE 3D printing [70]. The use of these dosage forms in a clinical
study paves the way for polymers already encountered in the food
and confectionary AM industries to be directly applied to pharma-
ceutical formulations made by AM. In material jetting, where poly-
mers can also be used as substrates often resembling flat films,
ethylene vinyl acetate, a polymer commonly used in transdermal
drug delivery system, could be a suitable polymer to apply [123].
This section has revealed that there are a few pharmaceutically
approved polymers, which are not yet commonly utilized in speci-
fic AM processes for oral drug delivery despite their potential suit-
ability. Furthermore, many polymers exist in several grades to
allow appropriate tuning of properties and extended utilization
across multiple AM technologies. To harness this advantage, com-9
plete characterization of the desired properties of polymers is nec-
essary. This can allow for optimization of polymer-process
compatibility and can potentially apply the wide range of available
polymers to the AM technologies they are not yet used in. The fol-
lowing section will exemplify a few trade-offs between printability
and product performance that only become evident when begin-
ning to apply polymers in AM to their intended pharmaceutical
applications.3. The role of polymers in product performance: Case examples
highlighting potential trade-offs between printability and
product performance
Pharmaceutical polymers are a bedrock in drug development
and their uses in developing dosage forms traverse various phar-
maceutical technology platforms [127]. This section aims at illus-
trating the complex role of polymers in AM, particularly with
regards to balancing printability and product performance in speci-
fic applications. The use of polymers to stabilize the drug in its
most appropriate solid state and the use of polymers in drug deliv-
ery applications are selected as two application examples, which
serve to elucidate the potential trade-offs between printability
and product performance that arise when translating AM technolo-
gies to pharmaceutical applications. Fig. 3 is an extension of Fig. 2,
where product performance has been added to the printability
depictions already present in Fig. 2, showing that a successful
AM process flow relies on the satisfaction of both printability and
product performance requirements.3.1. Trade-offs between printability and achieving and stabilizing the
solid state
The role of polymers regarding the solid state of products gen-
erated by pharmaceutical AM has primarily been reported as solu-
bilisation of the drug and/or stabilizing the amorphous form of
poorly soluble drugs upon amorphization by the AM technique.
However, achieving this alongside printability may be met with
key trade-offs, which need to be overcome to fully harness the
potential of polymers in AM for these functions. A few examples
will be discussed in this section in this regard.
Amorphization represents one means by which the apparent
solubility and dissolution rate of poorly-water soluble drugs can
be improved [128]. Several pharmaceutical AM technologies are
well-suited to inducing amorphization of drugs and/or polymers.
Fig. 3. Overview of desired polymer properties and examples of typical product performance attributes for various AM technologies. The figure is an extension of Fig. 2.
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melt-based DoD, and SLS, which provide sufficient energy input
to convert the drug from crystalline to amorphous form (Fig. 3).
Amorphization is not exclusive to melt-based AM. PAM or
solvent-based DoD may also induce amorphization at low drug
concentrations during the post-processing drying step.
Often, a binary system of polymer and drug is sufficient to
achieve and stabilize an amorphous solid dispersion [129,130].
When such systems are directly printable, further addition of10excipients is not necessary. However, in cases where the polymer
has too high a Tg for processibility in melt-based AM (see Sec-
tion 2.2.) or unsuitable mechanical properties for feeding as a fila-
ment in FDM (see Section 2.1.), additional excipients in the form of
plasticizers are commonly incorporated [131]. Although this
improves printability, plasticizers may compromise the physical
stability of the system during storage by causing phase separation
and subsequent recrystallization [132]. This is an example of a key
trade-off between printability and product performance, which
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pharmaceutical products. Another potential trade-off could occur
when solubilizers or precipitation inhibitors are added to improve
product performance by increasing bioavailability. These excipi-
ents often act as plasticizers, adversely influencing the mechanical
properties of filament for FDM, compromising feeding and there-
fore printability. Both these trade-offs show that balancing print-
ability and product performance is not a trivial task, with the
role of the polymer in eliciting desired product performance and
optimal printability playing a key role in this balancing act.
Sometimes, amorphization of the drug may not be desired or
necessary, for example, in the case of highly water-soluble drugs,
which may have better physical stability as crystalline solid disper-
sions [48]. Processing by AMmay inadvertently induce amorphiza-
tion of such drugs, compromising their physical stability. AM
processes, which do not provide excessive energy input to the sys-
tem are less prone to this phenomenon. An example includes
solvent-based DoD, which also tends to incorporate higher drug
loads, preventing unwanted amorphization.
Regardless of the polymer and process selection or modification
to achieve and stabilize the desired solid state, additional product
performance attributes, such as the target drug release profile,
must still be preserved, all whilst maintaining optimal printability.3.2. Trade-offs between printability and drug delivery
The role of polymers in formulation of conventional solid oral
dosage forms is to facilitate processing of the drug into a dosage
form and to tailor the release rate and site, amongst other product
performance attributes. This role is preserved during AM. Pharma-
ceutically approved polymers with different properties (hy-
drophilic, hydrophobic, amphiphilic, pH dependent, etc.) enable
manufacturing of systems ranging from conventional immediate
release tablets to modified release systems with different capabil-
ities, including sustained, delayed, extended, and pulsatile release
of the drug. Formulations can be tailored to specific release sites,
such as the stomach (e.g. floating or non-floating gastro-retentive
systems), the intestine (enteric-coated systems), or be designed
as dispersible or mucoadhesive systems. For a comprehensive
overview of polymers in controlled release in AM, the reader is
referred to a recent review by Borandeh et al. [21]. This section will
illustrate some of the trade-offs between printability and drug
delivery performance, with a few examples from the various AM
technologies.Table 3
Description of selected examples of immediate release formulations from different AM te
AM Technology Composition
FDM  5–20 % drug (caffeine)
 hydrophilic polymers (HPC, Kollidon VA64, Kollicoat IR
 plasticizer (PEG 4000)
 hydrophilic pore former (maltodextrin, xylitol)
PAM  24 % drug (carbamazepine)
 solubilizing polymer (hydroxypropyl-beta-cyclodextrin)
 hydrophilic polymer (HPMC, PVP, Na-CMC)
SLS  30% drug (clindamycin hydrochloride)
 Hydrophilic polymers (MCC, Kollidon VA64)
DoP  drug (amitriptyline hydrochloride)
 hydrophilic polymers (MCC)
 other powder excipients (lactose, dicalcium phosphate)
 hydrophilic binders (PEG, PVP)
DoD  drug (haloperidol)
 hydrophilic polymer (HPMC)
 porosity enhancer (mesoporous fumed silica)
 plasticizer (glycerol)
11As emphasized earlier, the AM technologies are based on differ-
ent working principles, which is reflected in the characteristic
attributes of the printed products. Despite flexible design options,
the melt-based technologies typically deliver printed formulations
with a high concentration of thermoplastic polymers in order to
meet the processability requirements. Such systems are typically
more suited to slow release of the drug (Fig. 3) [47,79]. For melt-
based printing, especially FDM, immediate release formulations
that disintegrate rapidly to release the drug are more challenging
to obtain than designing an extended release formulation. This is
due to the generation of typically nonporous prints via FDM, unless
porosity is designed into the model, for example, by varying infill
densities or compartments. Looking at conventional compressed
tablets, disintegration is facilitated by incorporation of hydrophilic
polymers that swell in contact with water, creating a volume
expansion that breaks up the dosage form into smaller fragments.
Typical tablet disintegrants, such as hydroxypropylcellulose,
crospovidone, carboxymethylcellulose sodium, and microcrys-
talline cellulose, are also used in printing of immediate release for-
mulations across the various platforms (Table 3). However, several
of these polymers lack appropriate thermoplastic properties for
printability via melt-based printing techniques, requiring addi-
tional excipients to increase their processability. Often, plasticizers
are included in formulations to improve processibility, especially
in extruded filaments for FDM, however their inclusion may
adversely alter not only the required drug release rate but also
the product stability as discussed in Section 3.1. and even the sur-
face texture of the printed product [48]. Once again, modification
to polymer systems to facilitate printability may come at a consid-
erable cost to final product performance, which is inadequately
addressed in current pharmaceutical AM research, if at all.
One approach to manage trade-offs could be appropriate selec-
tion of the AM technology. Continuing the example above, where
rapid disintegration is required as a product performance attribute
but the polymers which facilitate it are not suitable for one AM
process (FDM in the above example), they may be suitable for
another AM process. DoP printing resembles wet granulation,
where a binder solution is distributed over a powder bed, ‘‘gluing”
powder particles together to form larger structures. These larger
structures correspond to granules in wet granulation and porous
dosage forms in DoP (Fig. 3). As highlighted for Spritam, DoP is
highly suitable for the manufacture of rapidly disintegrating sys-
tems and typical tablet excipients may be used, e.g., with an
MCC-based powder bed and hydrophilic binder solutions (Table 3).
The main challenge for printed formulations from DoP is balancingchnologies.
Printed Structure Reference
)
 oblong shaped tablet
 one outer wall layer
 no top/bottom layer
 honeycomb infill pattern
 infill density 80%, 100%
[48]
 cylindrical tablet
 pore size 1 mm
[52]
 cylindrical tablet [42]
 filled cylindrical tablet [45]
 film substrate (prepared by solvent casting)
 DoD of ink solution
[65]
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case rapid disintegration with the desired mechanical strength
for handling and portability [45]. PAM can be considered as an
alternative solution in this case. Analogous to the parallels
between DoP and wet granulation, PAM may be compared to
another conventional manufacturing technology, namely, wet
extrusion for pelletization. Here, the powder mass is fully wetted
and the binder liquid confers suitable rheological properties to be
formable [52]. In order to achieve rapid disintegration in PAM,
hydrophilic polymers are used in combination with geometrical
designs containing voids, which could act as channels or pores
for hydration and subsequent release. In the absence of the avail-
ability of a printer with each type of working principle, this
extended case example shows that the future design of hybrid
printers with combined alternative working principles may be a
promising step in the right direction to manage trade-offs between
printability and product performance through ease of switching
between different working principles to process the wide range
of polymers currently available for achieving a range of desired
product performance attributes.
Compared to traditionally manufactured dosage forms, AM
enables the printing of geometries that provide improved control
over the available surface area for dissolution and drug release.
However, this requires processibility of the desired polymers into
final product geometries in a manner that closely represents the
CAD model, imposing strict requirements on printability of such
products. The geometric flexibility of AM also lends itself to the
design and fabrication of several innovative stimuli-responsive
systems, which change shape as a function of an external stimulus
[133]. Examples of external stimuli that induce changes to the
printed construct are temperature, ions, solvents, and time [134–
136]. The latter paves the way for a relatively unexplored area in
pharmaceutical AM, 4D printing, involving the fabrication of
objects via 3D printing that change shape, properties or functional-
ity as a function of time [135,137,138]. An interesting gastro-
retentive device is presented in Fig. 4 [135]. This PVA device has
a compressed helical shape, achieved using a 3D printed template,
that expands upon exposure to water, which plasticizes the poly-
mer, decreasing its Tg and allowing the expansion, which prevents
transport through the pylorus. 3D printed concepts have the
potential to expand the capabilities of AM to deliver advanced drug
delivery solutions. However, regarding innovative applications of
pharmaceutical AM, it is quite noticeable that the current literature
is yet to address and tackle existing trade-offs between printability
and product performance that may arise beyond proof-of-concept
demonstrations.
Through selected examples of polymer applications in pharma-
ceutical additive manufacturing, namely, achieving and stabilizing
the solid state and drug delivery, this section has demonstrated
that choosing the optimal polymer which simultaneously satisfiesFig. 4. Images of a helical PVA device inserted in a capsule and exposed to 0.1 N HCl at 37
its dimensions and breaks the capsule [135]. Reprinted with permission.
12the requirements of printability and the requirements for product
performance is no trivial task. Indeed, modifications to polymer
systems to improve printability may sometimes hinder product
performance and vice versa. This is one key reason why this review
is not a guidance on polymer selection. Instead, we have high-
lighted polymer properties that lend themselves to printability
for different AM processes and, through exemplification, how
selecting polymers or material systems with these properties
may not always result in the desired product performance.
Addressing trade-offs in this manner is highly recommended in
future to fill this knowledge gap and contribute to an improved
balance between printability and product performance across AM
technologies.
4. Characterization techniques used in additive manufacturing
Characterization techniques are multipurpose and their various
applications range from screening to identify suitable polymers,
process optimization [5,95], process monitoring in a Quality-by-
Design (QbD) approach [94,139,140], and intermediate and final
product quality attributes for subsequent optimization, for exam-
ple, mechanical strength [86,141–144] or target drug release pro-
files [103,142,145–147]. Depending on their intended purpose, a
range of characterization techniques are available and applied to
study raw materials (such as polymers) or formulations containing
drugs and/or polymers and/or non-polymeric excipients in the
form of physical mixtures, product intermediates like filaments
for FDM printing [141,142], or final dosage forms [139,140,148–
150]. Some techniques may demand a sample preparation step,
which modifies the material for subsequent analysis. Characteriza-
tion techniques also vary between those that are destructive and
those that are non-destructive to the sample, with the latter tech-
niques gaining favour in real time quality assessments. The sample
history plays a key role in determining the utility of the character-
ization technique for its intended purpose and at the very least
requires careful scrutiny of the results of the analysis. This section
introduces some of the most frequently encountered characteriza-
tion techniques in pharmaceutical AM and points out a few emerg-
ing techniques. The characterization techniques are already
primary applied to assess product performance and/or raw mate-
rial and pre-processed feedstock properties. We therefore highlight
their specific value in assessing the role of the polymer in printabil-
ity, where applicable. The techniques are categorized based on
material properties and the analytical principles used to assess
them. Table 4 provides an overview of these characterization tech-
niques with selected examples of their typical applications and
examples of the AM technologies they have been used in. Stan-
dardized characterization techniques that are essential for all solid
dosage forms, for example, assessing uniformity of mass, drug con-
tent, disintegration, and dissolution behaviour, have been excludedC at different times. The images illustrate how the shape of the prototype increases
Table 4
Overview of characterization techniques used in pharmaceutical AM with examples of their corresponding applications. TGA = thermogravimetric analysis, DSC = differential
scanning calorimetry, DMA = dynamic mechanical analysis, NIR = near infrared spectroscopy, FTIR = Fourier transform infrared spectroscopy, XRPD = X-ray powder diffraction,
WAX = wide-angle X-ray scattering, SANS = small-angle neutron scattering, SEM = scanning electron microscopy, X-ray mCT = X-ray computed microtomography, TPI = terahertz
pulsed imaging, ToF-SIMS = time of flight – secondary ion mass spectroscopy, Tdeg = degradation temperature, Tg = glass transition temperature, Tm = melting temperature, E’=
tensile storage modulus, E’’= tensile loss modulus, G’= shear storage modulus, G’’= shear loss modulus.
Characterization Techniques Example of Application AM Technology
Thermal techniques TGA Solid state (e.g. Tdeg) FDM [151–155],
PAM [156],
SLA [157]






DMA Viscoelasticity (e.g. E’, E’’), solid state (e.g. Tg) FDM [73,86,130]










Stiffness and brittleness balance for feeding of
intermediate filament








Indentation Final product viscoelasticity FDM [167,168],
PAM [169]
Interlayer adhesion Interlayer strength FDM [140,146,170]
Rheological techniques Flow test Feeding, deposition, and adhesion





Capillary test Feeding, deposition, and adhesion





Frequency sweep Feeding, deposition, and adhesion




Creep test Creep and die expansion or swelling FDM [73],
PAM [36]
Surface tension Pendant drop Optimization of droplet DoD [111,173]
du Noüy ring DoD [85]
Spectroscopic techniques NIR incl.
NIR chemical imaging
Drug content and distribution FDM [175]
SLS [176]
DoD [177]




Raman incl. mapping and confocal
Raman microscopy










WAXS Solid-state FDM [155],
PAM [160]
SANS Nanostructural information FDM [185]











TPI Microstructure information FDM [186]
ToF-SIMS Spatial mapping of drug DoD [161,187,188]
Computational
techniques
Machine learning Prediction of printing conditions and release rate of drug FDM [139,189]
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products and are frequently employed to assess product perfor-
mance in AM, as well-established Pharmacopoeial methods, they
are not printability specific. Also, product-focused techniques for
evaluation of chemical stability of the drug, polymer and other
excipients, e.g., HPLC-based methods, are considered out of scope.
Several of the relatively simple and discrete characterization
techniques highlighted in this section can be applied in a complex
context, for example, serving as process analytical technologies
(PAT) for real-time monitoring of an AM process or used for cali-
bration and/or validation of in silico simulations and other digital
methods. Such advanced applications are further discussed and
exemplified in Section 4.8.
4.1. Thermal techniques
In the AM technologies which apply heat to the polymer,
namely, FDM, melt-based DoD, and SLS, thermal transitions, such
as Tg, Tm, and Tdeg, are crucial to defining the optimal processing
window for printability and product performance [87]. Thermo-
plastic polymers, with their relatively low Tm or Tg, are central
excipients for these AM technologies [73,86,87]. However, for
pharmaceutical AM, they are not typically used alone but instead
contain the drug to form a solid solution of the drug molecularly
dissolved in the polymer or a solid dispersion with the drug in
crystalline or amorphous form. Importantly, the drug may alter
the position of thermal transitions relative to those of the pure
polymer, which may require defining of processing windows speci-
fic for each composition. The application of polymers in AM to
achieve a particular solid state was discussed in Section 3.1. of this
review. Three thermo-analytical techniques will be discussed in
this section, namely thermogravimetric analysis (TGA), differential
scanning calorimetry (DSC), and dynamic mechanical analysis
(DMA), where the first two are the most frequently used.
4.1.1. Thermogravimetric analysis (TGA)
TGA measures changes in mass of a sample, specifically mass
loss, as a function of temperature or time in a controlled atmo-
sphere [190]. A typical thermogravimetric analyser achieves this
by heating a sample at a predefined rate in a closed furnace and
continuously measures its mass with a precision balance. The
resulting TGA thermogram is expressed as mass or percentage of
initial mass versus temperature or time. As such, mass loss occur-
ring due to evaporation or thermal decomposition, for example,
can be ascertained. For AM printing, determination of the onset
of thermal degradation, assigned Tdeg, defines the upper limit of
processing temperature range to ensure thermal stability of the
material [152,178]. TGA is a destructive analytical technique,
which can be applied to raw materials, physical mixtures, interme-
diates or pre-processed feedstocks, and final products [151–153].
Below, Tdeg, it may also be possible to perform multiple heating
runs in a single TGA experiment to reveal the effect of double heat
processing (e.g. hot-melt extrusion (HME) followed by FDM) on
both the physicochemical stability and processing range of various
materials. In addition, isothermal TGA measurements can provide
valuable information on the effect of prolonged heating during
printing, for example, when deposited polymer is in contact with
a heated build-plate [191]. Even for AM technologies which do
not typically apply heat directly to the polymer during processing,
e.g. PAM, TGA can potentially provide information regarding the
time and temperature required for desolvation and drying of final
products during post-processing steps.
Due to its measurement principle, it follows that TGA is less
useful for degradation that does not result in mass loss, even
though such degradation defines material stability and could influ-
ence mechanical properties. To determine the stability of polymers14for SLS, a novel technique called stability estimate by crystalliza-
tion analysis, has been introduced [192]. Based on fast scanning
calorimetry, it is capable of heating materials by several thousands
of Kelvins per second with the instrument time constants in the
millisecond range, making it particularly useful for the short tem-
perature exposure times in SLS. Even though not stipulated for
other AM technologies, it could be advantageous for studying poly-
mer stability during the short residence times encountered in the
heated nozzle in FDM during rapid printing.
4.1.2. Differential scanning calorimetry (DSC)
DSC measures the difference in heat flow to a sample and a ref-
erence that is required to maintain both at the same temperature
as the sample undergoes physical transformations, like phase tran-
sitions upon heating [193]. The total heat flow is proportional to
the heat capacity of the material being analysed. Like TGA, DSC is
also destructive to the analysed sample, which can be a raw mate-
rial, physical mixture, intermediate or pre-processed feedstock, or
final product. The resulting thermograms are expressed as a heat
flow versus temperature. Several typical transitions can be
observed in a DSC thermogram to determine the Tm (of crystalline
polymers, crystalline parts of semi-crystalline polymers, or crys-
talline drugs), Tg (of amorphous polymers or amorphous regions
of semi-crystalline polymers), dehydration, or relaxation, which
are all endothermic transitions [190]. Exothermic transitions such
as recrystallization of amorphous systems are also determined
using DSC [190,193].
Heat flow analysis can be performed with a conventional DSC or
a modulated DSC (mDSC). In the case of the latter, the difference in
heat flow between a sample and reference is also measured as a
function of temperature or time, however, unlike conventional
DSC, mDSC applies a sinusoidal temperature modulation of prede-
fined period and amplitude overlaying the linear heating profile.
The consequence and advantage of applying this sinusoidal modu-
lation over the linear temperature programme is that overlapping
thermal transitions e.g. enthalpic relaxation, which could mask the
glass transition in conventional DSC, can be resolved with mDSC
[194].
For printability, DSC is particularly useful for determining the
lower limit of the processing window, as defined by the Tg or Tm
of the polymer. This lower processing temperature limit can also
be altered through the addition of the drug or other excipients to
the polymeric matrix, if plasticization occurs [159,195]. DSC can
also be used to evaluate the thermodynamic solubility of the drug
in the polymer [196]. This is important when developing formula-
tions for heat-based AM techniques, since determining the amount
of drug that is thermodynamically soluble in the polymer [197] is
not just crucial for product performance but could also influence
the efficiency of plasticization for improved mechanical properties
of filaments for FDM (addressed in Section 4.2.) or altered rheolog-
ical properties of droplets in melt-based DoD (addressed in Sec-
tion 4.3.), for example.
4.1.3. Dynamic mechanical analysis (DMA)
DMA is a thermo-mechanical technique, which applies sinu-
soidal stress under a predefined frequency and temperature pro-
gramme, to deform a sample and measure its strain response
[198]. Specifically, DMA determines the phase angle between the
applied sinusoidal stress and the resulting strain, from which vis-
coelastic behaviour is determined. This is translated to complex
modulus via a mathematical treatment. A DMA thermogram pre-
sents the complex modulus as a function of either temperature,
time, or frequency.
DMA can be performed on samples in the form of films or pow-
ders. The introduction of powder sample holders means that the
utility of DMA can also be extended towards unprocessed raw
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from determinations of Tg and molecular mobility, viscoelastic
properties, moisture content and its influence on complex modu-
lus, dehydration of crystalline hydrates, crystallinity, and miscibil-
ity between polymers [65,73,86,198–203]. Many of these are key
contributors to both product performance and the definition of
processing parameters or screening of polymers for printability.
For example, Tg determination by DMA can be used to define the
lower temperature limit for printability using the AM technologies
that apply heat to materials during processing. Indeed, specific
thermal phenomena, such as the Tg, can be probed with DSC,
DMA, or even dielectric spectroscopy [204], which all have differ-
ent measuring principles and result in different absolute process-
ing temperature ranges being reported for the same polymer
[199,204,130]. Therefore, defining optimal thermal processing
ranges to ensure printability and product performance requires
careful consideration of the technique from which this information
is derived.
4.1.4. Defining printing temperature windows from several thermal
techniques in combination
Combining complementary information from TGA, DSC, and
DMA allows the complete thermal processing range for printability
to be defined (Fig. 5) [130]. Typically, during pharmaceutical AM,
DSC and/or DMA is used to define the lower temperature limit
for deposition through the nozzle in FDM and melt-based DoD as
well as for adhesion to the build-plate, both based on Tg range
determinations [205], whereas TGA is used to define the upper
temperature limit of the processing range.
4.2. Mechanical and powder flow techniques
Mechanical tests are primarily relevant for optimizing and
assuring final product performance. Analogous to solid dosage
forms fabricated by conventional pharmaceutical manufacturing
techniques, the mechanical properties of printed dosage forms
should be within acceptable limits to facilitate handling, transport,
and storage without breakage or material loss [15]. The European
Pharmacopoeia (Ph.Eur.) describes two tests for the evaluation ofFig. 5. Illustration of the combination of TGA, DSC, and DMA thermograms
15mechanical strength of solid dosage forms, namely Friability of
uncoated tablets (Ph.Eur. 2.9.7) [206] and Resistance to crushing of
tablets (Ph.Eur. 2.9.8) [207], both of which are applicable to all
printed products, especially those that result in porous or fragile
final dosage forms e.g. dosage forms fabricated by DoP printing
or SLS (Fig. 3 and Table 4).
In addition to final product performance across all AM technolo-
gies, mechanical characterization plays a key role in determining
printability of filaments for FDM [73]. During FDM, polymers
which are extruded into brittle filaments are often incompatible
with the rotating drive gears encountered in a typical FDM feeding
mechanism, preventing automated feeding and optimal printabil-
ity [208]. Here, mechanical tests which can assist in achieving an
appropriate stiffness-flexibility-brittleness balance of the interme-
diate filament is essential for printability [29,73,87,144]. To the
best of the authors’ knowledge, no reports which systematically
compare feeding of the same polymer through the drive gears of
different FDM printers are available, however, it can be expected
that different feeding mechanisms in different brands of FDM
printers would alter what constitutes optimal measurement values
for various mechanical properties. This section will highlight a few
mechanical and powder flow techniques that are typically encoun-
tered in pharmaceutical AM literature.
4.2.1. Compression, tensile, and indentation tests
Compression, tensile, and indentation tests are performed with
instruments that can record time-resolved force and displacement,
for instance, a texture analyser or a material tester (Table 4),
resulting in stress–strain profiles from which further information
on the tensile strength, elongation to break, and Young’s modulus,
can be derived. The main differences between these tests lie in the
different test setups and whether the applied force is compressing,
extending, or crushing the sample. Filaments for FDM printing
undergo both compressive and tensile forces under the applied
force of the feeding drive gear. Compression tests provide valuable
information on the material’s resistance to crushing, similar to Ph.
Eur 2.9.8. [207], for printability, in the case of FDM, and for final
product performance, in the case of all AM technologies. There
are different compression test methods including three-pointfor defining the optimal processing temperature range for printability.
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tests [158], which can all be performed on filaments for FDM print-
ing. By analysing filaments in different orientations, they can be
used to determine the stress at which plastic to elastic deformation
occurs or at which a filament breaks [142,144]. In contrast to com-
pression tests, tensile tests apply a force to extend the sample until
rupture. Although tensile tests are typically used to determine the
flexibility of thin samples, such as films [157], their use can, in
principle, be extended towards material systems encountered in
AM. Here, they can potentially be used to predict the flexibility
of polymers to be extruded into filaments for FDM without the
material wastage that occurs with larger batch sizes of potentially
brittle filaments via melt extrusion upstream of FDM. Tensile tests
may also offer value in determining the flexibility of polymers to
be used as substrates in material jetting, which may, for example,
require folding or rolling to fit into a capsule post-printing.
Although compressive and tensile tests crush and rupture the sam-
ple, respectively, insight into material properties can also be
obtained without sample destruction. Indentation tests position a
small-diameter probe onto the sample and apply a compressive
force until a pre-defined force value or displacement value is
achieved. From this, the material’s ductility and elastic properties
can be determined.4.2.2. Interlayer adhesion test
To evaluate the interfacial adhesion force between printed lay-
ers (discussed in Section 2.3), typical adhesion tests apply a force
perpendicular to the layers of a printed structure. Alternatively,
interlayer adhesion may be evaluated in tensile mode, where the
upper and lower parts of an object are pulled apart until a detach-
ment force is recorded. Due to the layer-by-layer deposition that
characterizes AM technologies, the maximum interfacial adhesion
force is relevant for most AM technologies and can provide a mea-
sure of adhesion either between layers of the same composition or
between layers of different compositions [140,146,170], such as in
multidrug dosage forms.Fig. 6. Overview of polymer rheology, associated characterization techniques, and releva
G00= shear loss modulus).
164.2.3. Powder flow
For all AM techniques involving the mixing and/or feeding of a
powder, powder flow properties are crucial for obtaining consis-
tent and homogeneous prints. Standard methods to assess powder
flowability, such as flow rate through an orifice (g/sec), angle of
repose, and estimation of the Hausner ratio or Carr index (derived
from the bulk and tapped density of the powder), can be applied
[209].4.3. Rheological techniques
It is well established that polymers exhibit different rheological
properties depending on a number of factors, including the chem-
ical and physicochemical structure of the material itself, the phys-
ical state of the material (e.g. solid versus liquid), concentration of
the material (e.g. melt/concentrated solution, semi-dilute solution,
dilute solution), the environment (e.g. temperature, pressure), and
the strain history. Although the physical state of the material and
the polymer concentration in the formulation can vary widely
between different AM technologies, ranging from the sintered solid
polymers in SLS to molten polymers in FDM andmelt-based DoD to
semi-solid gels or pastes in PAM to dilute solutions in DoP printing
or solvent-based DoD printing, the basic flow theory remains the
same. Fig. 6 provides an overview of polymer rheology, as a guide
for the discussion in this section.
Viscosity describes the resistance of a material to flow and is
modulated by shear and/or temperature, where shear viscosity is
the ratio of shear stress to shear rate. Elasticity describes a mate-
rial’s internal resistance to deform and restore its original state
when the applied force is removed. Polymers are viscoelastic and
therefore exhibit the viscous properties of liquids and the elastic
properties of solids, depending on the timescale of the deforma-
tion. Viscoelasticity is expressed as a shear storage modulus (G’,
elasticity) and a shear loss modulus (G’’, plasticity). Due to the
time-dependent plasticity component, polymers respond differ-
ently to different shear stresses and shear rates. However, due tonce in AM (c = concentration, c* = overlap concentration, G0= shear storage modulus,
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erties over time. In oscillatory tests, the time dependence can be
evaluated by varying the frequency of the applied stress or strain,
with high frequencies corresponding to short time scales and low
frequencies corresponding to longer time scales. Insight into these
parameters allows better prediction of a polymer’s behaviour dur-
ing processing [90,91,94,210].
For melt-based AM technologies, where thermoplastic poly-
mers are typically the major component in the formulation, tem-
perature is used to soften or melt the polymer, with a
corresponding change in its viscosity [67,76,90]. Several recent
publications, which emphasize the importance of melt rheology
during melt extrusion, are equally applicable to melt-based AM
[94,95,171]. The temperature required in FDM printing is often
higher than in HME because of the lower shear in the printer extru-
der combined with low residence time in the nozzle compared to
HME [94]. To assess rheological properties of melts temperature-
controlled rheometers are used in various configurations, including
parallel-plate and cone-plate geometries [95,171,211]. Typical
parameters assessed are complex viscosity and storage and loss
moduli. Melts and concentrated polymer solutions have similari-
ties in characterization techniques and assessed parameters and
are therefore categorized together (Fig. 6).
Another relevant parameter for extrusion-based AM technolo-
gies, including PAM, is the yield point, above which the material
starts to flow [5,94]. Too low viscosity will result in uncontrolled
deposition of material from the nozzle. High viscosity would
necessitate higher forces to push the material out of the nozzle,
resulting in excessive shear forces being exerted on the material.
Too high viscosity could inhibit deposition altogether. Beyond
uneven deposition, inconsistent and suboptimal flow could entrap
air within the printed product or result in inhomogeneous and
poor-quality prints. Undesirable viscoelastic behaviour can also
result in creep and die expansion, both of which are likely to gen-
erate products with inaccurate dimensions and/or poor dimen-
sional stability [36,73,95]. During PAM, the polymer exists in a
semi-solid state as various forms, for instance, gels, pastes, or
emulsion gels [95,172,174]. Typically, the polymer chains overlap
(c > c*) in a semi-dilute solution forming a three-dimensional net-
work from polymer chain entanglements. Therefore, in addition to
viscosity and yield point, gel strength is also crucial for controlling
deposition from the PAM nozzle. Both oscillatory measurements in
rheometers and rotational viscometers can be used to characterize
semi-dilute systems, depending on the polymer concentration as
well as the content of fillers or dry excipients in a formulation.
Low polymer concentrations forming dilute polymer solutions,
where the polymer chains do not interact with each other
(c < c*), could be encountered in solvent-based DoD or DoP printing
if polymers are included in the solvent. Here, an optimal viscosity
contributes to the controlled deposition of primary droplets with-
out the generation of unwanted satellite droplets [109]. Alongside
viscosity, surface tension is another useful parameter to assess
drop dynamics (Section 4.4). Dilute polymer solutions typically
show plastic or pseudoplastic flow with a yield point. Shear thin-
ning effects are also frequently observed. These systems are evalu-
ated with either rotational viscometers or simple capillary
viscometers, such as Ubbelohde or Ostwald viscometers [212].
Rheological analyses have been shown to provide a deeper
understanding of processability of the polymer or formulation
[5,10,141,147,149,174,213]. Rheological tools are also useful for
formulation development, for studying drug-polymer interactions
[7,210,214], polymer blends [210,214], the effect of added excipi-
ents [215], and for tailoring and predicting product performance,
such as dissolution and drug release behaviour [103,139,147]. Sev-
eral options exist to optimize the rheological properties specific to
the AM process of interest. These include a combination of process17parameters (e.g. temperature, printing rate) and formulation
parameters (e.g. polymer type-considering chain flexibility,
branching, chain length, Mw; mixing of polymers-considering dif-
ferent copolymer ratios, Mw; and addition of drug(s) and excipi-
ents such as plasticizers or fillers) [103,171,210,216,216].
Although rheological characterization is performed routinely in
the polymer industry to evaluate processability of polymers, it
remains somewhat underutilized in pharmaceutical additive man-
ufacturing [95].4.4. Techniques to measure surface tension
Drop dynamics is a crucial part of printability during melt-
based and solvent-based DoD printing, where surface tension is a
key property, alongside viscosity [4,108,110,217]. Here, measure-
ments of surface tension by drop shape analysis [111] or tensiom-
etry [218] for example, by utilizing a du Noüy ring [85], have been
reported (Table 4). In the case of the former, the pendant drop
method has been used. Here, both the surface tension and weight
of a droplet contributes to its shape when suspended from a nee-
dle, therefore, by analysing an image of the drop, its surface tension
can be determined. In addition, several dimensionless quantities
exist to characterize drop dynamics including the Reynolds num-
ber, Weber number, Ohnesorge number, and Fromm’s number
[67]. Although lower and upper limits for acceptable values exist
for Newtonian fluids, more research is required to determine what
values are considered optimal for viscoelastic liquids such as poly-
mer melts during melt-based DoD [67]. Contact angle measure-
ments have also been utilised to ascertain whether the material
has an appropriate surface tension for optimal adhesion [3].
Regardless of whether solvent-based or melt-based DoD print-
ing is employed, the surface tension of the liquid at the nozzle
needs to be sufficiently high to prevent leakage from the nozzle
orifice when deposition is not occurring, to form spherical droplets
after liquid is ejected as a jet from the nozzle, and to prevent
potentially undesirable spreading and droplet coalescence onto a
substrate during adhesion [100,109,110]. At the same time, surface
tension needs to be sufficiently low such that the pressure pulses
originating from piezoelectric, electrostatic, or thermal actuators
can overcome the surface tension to eject the droplets during
deposition [5]. Surface tension also influences refilling of the drop
generator, together with viscosity [100]. Although most studies in
pharmaceutical AM relate surface tension to DoD printing, surface
tension measurements are not exclusively applicable to DoD tech-
nologies. They may also be advantageous in understanding adhe-
sion to a build plate, substrate, or previous printed layer, which
has been harnessed during FDM [87]. Surface tension is also crucial
for successful printing during SLS. Here, low melt surface tension is
desirable to encourage coalescence between powder particles [13].4.5. Spectroscopic techniques
Rapid, specific, and non-destructive analytical techniques for
assessment of drug content, drug distribution, and the solid-state
form of drugs are desired in quality control of all pharmaceutical
products. Selected spectroscopic methods are highly attractive
since they can be used for real-time analysis in-line and on-line
during processing, in addition to or as an alternative to off-line
analysis [219]. As such, the spectroscopic techniques are key tools
in PAT (see Chapter 4.8.1). In this section, the vibrational spectro-
scopic methods near infrared (NIR), Fourier-transform infrared
(FTIR), and Raman spectroscopy will be discussed, and their use
in AM exemplified. FTIR and Raman are often considered comple-
mentary techniques. In order to extract and quantify information
in an efficient manner, spectral data are often accompanied by
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[220,221].
4.5.1. Near infrared spectroscopy (NIR)
NIR spectroscopy is a rapid and non-destructive analytical tech-
nique with wide and varied applications in pharmaceutical analy-
sis. This technique is based on the absorption of electromagnetic
radiation from the visible (780 nm) to the mid-infrared region
(2500 nm) [220]. NIR spectra comprise chemical information (e.g.
content of drug, content of excipient, contamination, water con-
tent, and batch-to-batch variability), physical information (e.g.
crystalline form, polymorphism, and particle size), and is fre-
quently applied for process monitoring (e.g. of chemical or physical
information, end-point detection) (Ph.Eur. 2.2.40. Near-infrared
spectroscopy) [222]. Its use in combination with AM can be found
across different technologies with an emphasis on product perfor-
mance. For example, Trenfield et al. quantified the drug content in
SLS printed dosage forms with NIR [10], Vakili et al. used NIR
hyperspectral imaging to study inkjet printed systems [177], and
Khorasani et al. created chemical maps of drug and excipients by
NIR chemical imaging for the prediction of the spatial distribution
of drug in FDM printed films [175].
4.5.2. Fourier transform infrared spectroscopy (FTIR)
FTIR is another rapid and non-destructive analytical technique
based on the absorption of infrared radiation. FTIR operates by con-
verting a time domain interferogram to a frequency spectrum. The
spectrum serves as a fingerprint of a molecule and can be used to
elucidate molecular structure and reveal interactions between
molecules [223]. FTIR is often used to examine possible interac-
tions between the components of the formulation, such as the drug
and the excipients. This is not the most widespread method in AM
but has still been used in a variety of the technologies, such as FDM
[68,178,179], PAM [39], SLA [116], and solvent-based DoD [111].
4.5.3. Raman spectroscopy
Raman spectroscopy is a versatile non-destructive analytical
technique that uses the secondary radiation ‘‘Raman scattering”
to determine vibrational modes of molecules [224,225]. The hyper-
spectral information provides a structural fingerprint from which
chemical identity, quantitative analysis, and solid-state form of
drug molecules can be extracted [226]. As stated in the Ph.Eur.
(2.2.48. Raman spectroscopy), Raman spectroscopy is useful for
chemical, physical, and process analysis [227]. Coupling a Raman
spectrometer with fiber-optic probes allow operational flexibility
and remote systems that can be built into equipment for process
monitoring. They can also function as small hand-held equipment
for rapid analysis [224,225]. Raman microscopes can perform
localized sample analysis, enabling hyperspectral chemical imag-
ing or mapping, whereas confocal Raman microscopy can also dis-
criminate axial signals originating from selective depth within the
sample [224]. Although Raman has been used to monitor HME pro-
cesses [228,229], to the best of our knowledge, it has not yet been
implemented into FDM printers. Nevertheless, Raman spec-
troscopy has widespread use in confirming the product perfor-
mance of 3D printed products. For example, Raman mapping has
been used to assess drug distribution and solid-state form of the
drug in FDM [82,147,180], in melt-based DoD [66], and in SLS
[176]. Other authors have use confocal Raman microscopy for the
evaluation of FDM printed matrices [178] and solvent-based DoD
[111,161].
4.6. Scattering techniques
Pharmaceutical polymers processed by AM are available in
amorphous or semi-crystalline form. AM processing can intention-18ally alter the solid-state form of the polymer (e.g. from semi-
crystalline to amorphous form in melt-based AM), unintentionally
alter the polymer solid state form, or even aid in maintaining the
polymer in its original solid-state form, if desired. Scattering tech-
niques are typically used to evaluate the solid-state form of drugs
during pharmaceutical AM but this property is also strongly influ-
enced by the type and concentration of polymer that is incorpo-
rated into the AM formulations. Current applications of scattering
techniques are used almost exclusively for product performance
and stability, not printability. This section summarizes X-ray pow-
der diffraction (XRPD), small-angle x-ray scattering (SAXS), wide-
angle x-ray scattering (WAXS), and small-angle neutron scattering
(SANS) with a focus on the polymer solid-state. XRPD is currently
the most widespread of these in AM. Since this review focuses on
the role of polymers for printability rather than only product per-
formance, these techniques will only be briefly addressed for infor-
mation purposes.
4.6.1. X-ray powder diffractometry
An X-ray diffractometer is equipped with an X-ray tube for gen-
erating X-ray radiation. The emitted X-rays interact with the sam-
ple, placed on a sample stage, and are diffracted. The intensity of
the diffracted beam is then recorded by a detector at various
diffraction angles. During diffraction of crystalline materials, long
range molecular order is present, which produces a constructive
interference pattern. This interference pattern is read out as peaks
in the diffractogram [230]. The diffraction pattern for a crystalline
form is unique, therefore X-ray diffractometry can be used for
material characterization and crystal structural elucidation [230–
232]. For amorphous materials, which lack long range molecular
order, no constructive interference occurs, resulting in a halo pat-
tern in their diffractogram [230]. Several pharmaceutical polymers
are either amorphous or semi-crystalline and are therefore charac-
terized by either a halo or low intensity diffraction peaks, respec-
tively [233]. In AM, when a crystalline drug is embedded in the
amorphous polymer, less intense diffraction peaks have been
observed [183,233–235]. For the purposes of product performance
and stability, X-ray diffraction can be performed under varying
temperatures and/or humidities [232].
4.6.2. Small- and wide-angle X ray scattering and small-angle neutron
scattering
WAXS can provide similar information to XRPD on the solid-
state form of the polymer [155], without requiring sample milling.
SAXS probes considerably smaller angles thanWAXS [236], provid-
ing information on longer length scales, for example, thickness of
amorphous or crystalline layers, which may be useful to probe
heterogeneity in intermediates or final products. In the case of
the former, this could clarify the processibility or lack thereof of
certain material systems. Furthermore, scanning SAXS can poten-
tially be used in future to study controlled spatial deposition of
drugs and polymers with different solid-state forms during AM
printing.
SANS is a technique that has been used previously to under-
stand structures on a nanometer scale, which has been related to
properties of interest in FDM-printed constructs outside of pharma
[185]. In pharmaceutical AM, it may, for instance, be applied sim-
ilarly to study polymer alignment and orientation at the interface
between printed layers or troubleshoot potential printability
issues related to structure, such as delamination.
4.7. Imaging techniques
Most microscopic imaging techniques are non-destructive and
have a long history in the study of pharmaceuticals. Various imag-
ing techniques have proven useful in visualising and understand-
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bution, and feature dimensions, on surfaces and sections of 3D
printed products and solid intermediates [153]. As mentioned in
Chapter 4.5., both NIR and Raman are also used for imaging or
mapping [111,147,175,177].
4.7.1. Scanning electron microscopy (SEM)
One of the most prevalent imaging techniques is scanning elec-
tron microscopy (SEM). SEM uses an electron microscope to scan
sample surfaces or sections with an electron beam. These electrons
interact with the sample, producing backscattered and secondary
electrons, which are used to generate a 2D image containing com-
positional, topographical, and morphological information on the
sample, for example surface roughness, porosity, layer height,
and layer structure [237,238]. Although SEM techniques generate
a 2D image, they may provide a 3D impression of morphological
features. In addition to providing information about final product
quality and performance, for example, by elucidating the
microstructure to explain mechanical properties or drug release
[178,239], SEM can also be used to reveal potential relationships
between filament microstructure and feeding during FDM.
In addition, other forms of SEM imaging such as focused ion
beam-SEM and SEM with energy dispersive X-ray analysis [240
236,241] can be used to study the distribution of drug and polymer
in extruded filaments for FDM or polymeric substrates with depos-
ited drug in DoD printing, which can provide insights into the flex-
ibility or physical stability of these printed products.
4.7.2. X-ray computed microtomography
X-ray computed microtomography (X-ray mCT) is a non-
destructive 3D imaging technique that has gained significant use
in visualizing 3D printed samples. It is based on the principle that
an object will attenuate incident X-rays to different extents in
regions with different densities. The resulting 2D shadow projec-
tions are subsequently reconstructed to generate a 3D X-ray image
[242]. One of the major uses of X-ray mCT is the determination of
porosity in 3D printed constructs. Due to the high geometric design
flexibility of several AM processes, an internal pore network can be
intentionally designed into the 3D printed construct, if desired, to
modulate drug release kinetics, for example. In addition to porosity
determination, X-ray mCT can be used to determine the structural
integrity of printed constructs. Its non-destructive nature and abil-
ity to generate 3D visualizations makes X-ray mCT especially suit-
able for geometric assurance, i.e., to determine how closely the
printed object resembles the intended CAD model [50,180]. Modi-
fication of process parameters and material inputs can thereafter
be carried out to optimize printability and product quality.
4.7.3. Emerging imaging techniques
More advanced imaging techniques are also explored for
printed pharmaceuticals. Using time of flight – secondary ion mass
spectroscopy (ToF-SIMS), microscale heterogeneity between sur-
faces and bulk can be revealed, which can provide insights into
potential physical instability or crystallization of the drug
[161,187,188]. In addition, spatial mapping of drug distribution
as a function of depth can be obtained, which has been shown to
provide complementary evidence to Raman spectroscopy within
the bulk of printed structures by melt-based DoD [161,187]. Since
ToF-SIMS is surface sensitive, with a measuring depth of approxi-
mately 1 nm, typically only substances on the surface can be ana-
lyzed. However, ToF-SIMS has also been used in combination with
focused ion beams to probe the chemical interface between printed
surfaces containing silver nanoparticles and polymers like poly-
styrene or poly(methyl methacrylate) [187]. Scoutaris et al. have
also shown that is possible to determine the chemical content in
dry ink-jet droplets containing both drugs (felodipine and19hydrochlorothiazide) and polymers (PVP, PLGA) by using ToF-
SIMS [243].
Terahertz pulsed imaging is based on the reflection of terahertz
pulses as they encounter media with different refractive indices
[186,244]. This technique has been used to determine coating layer
thickness on solid dosage forms [244,245]. Terahertz radiation is
capable of penetrating most polymers. Recently, Markl et al.
showed that this non-destructive imaging technique is another
option to characterize microporous structures within 3D printed
products [186].
4.8. Advanced use of characterization techniques for complex
applications
Several of the simple characterization techniques described
above in Section 4 can also be combined and implemented for
more complex purposes, such as process monitoring in a PAT
approach or combined with computational methods or digital tools
to calibrate and validate models for in silico simulations and pre-
dictions. Examples of such applications within AM are addressed
in the following sub-sections.
4.8.1. Process analytical technology (PAT)
Implementation of PAT to monitor AM processes and secure
critical quality attributes (CQAs) in the final product has been
explored in a Quality-by-Design (QbD) approach. PAT tools are
intended to rapidly and non-invasively collect and analyse data
in real-time. To this end, spectroscopic techniques, such as Raman,
near infrared, and UV/Visible spectroscopy have been employed in
the study of drug content, content uniformity, and degradation-
induced changes in the solid state, to name a few examples
[73,228,229,246]. The spectroscopic techniques are generally rec-
ognized among the main PAT tools and are even described in the
recent monograph on PAT in the European Pharmacopoeia (Ph.
Eur. 5.25. Process analytical technology) [247]. They are considered
key elements of pharmaceutical continuous manufacturing [248].
Recently, several reviews on pharmaceutical AM technologies also
discuss the PAT tools required for continuous manufacturing. For
example, Bandari et al. discuss the coupling of HME and FDM to
a continuous line [29], Rahman and Quodbach discuss the required
PAT tools for PAM [30] and Awad et al. does the same for SLS [32].
In this context, not only are spectroscopic PAT tools needed but
techniques that specifically provide real-time information on pro-
cessability and/or identification of failure modes leading to geom-
etry defects whilst processing, would have considerable potential,
and should be further explored. The following paragraphs provide
a few examples to highlight the value of other PAT tools for phar-
maceutical AM.
Various imaging techniques using cameras or laser profile sen-
sors can be applied in-line to track the printed geometry using dig-
ital image analyses. Real-time images can therefore be
continuously compared with the CAD model to identify printing
defects and errors [43,45,249]. For melt-based AM technologies,
thermal imaging may prove particularly beneficial in providing
information on potential hotspots, which could lead to thermal
degradation [73]. Thermal imaging could also be useful for moni-
toring the cooling phase in melt-based AM. Optimal cooling is crit-
ical to solidify the printed product and avoid deformation under its
own weight whilst at the same time facilitating optimal adhesion
to the build-plate, substrate, or preceding printed layer [171].
For extrusion-based techniques, in-line pressure transducers
are useful tools to monitor material flow [94,171]. Nozzle clogging
is a frequently occurring process error that could impact the result-
ing geometric accuracy and mechanical properties of the printed
construct. Tlegenov et al. proposed a dynamic model for current-
based nozzle condition monitoring [249]. Anderegg et al. designed
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ture and flow rate to reduce fluctuations in pressure during FDM
processing [250]. Recently, in-line rheological monitoring for
FDM was described by Coogan and Kazmer [94,140]. Here, a mod-
ified printer nozzle with an invasive thermocouple and pressure
transducer provided real-time monitoring of melt temperatures
and viscosities encountered during FDM processing. Translating
several such developments from non-pharmaceutical AM to phar-
maceutical applications will likely provide a considerable step for-
ward in the widespread implementation of controlled
pharmaceutical AM processes.4.8.2. In silico techniques and other digital tools
Pharmaceutical AM technologies are actively moving towards
integrating more computational methods and digital tools to pre-
dict and optimize process parameters, eliminate material usage,
reduce trial and error, and improve cost- and time-efficiency, to
name a few examples. Nevertheless, all computational approaches
require calibration and/or validation with experimental data at
some point. In this section, the potential or established utility of
simulations, digital twins, artificial intelligence, and specifically,
machine learning, will be addressed. Where relevant, their contri-
bution to elucidating or optimizing the role of the polymer in AM
will be highlighted. The interested reader is referred to a recent
review on artificial intelligence for pharmaceutical AM [251].
Simulations play an important role in predicting experimental
outcomes, such as the influence of material properties on printabil-
ity and product performance, in a rapid and efficient manner. By
attaining practical feedback through simulations, the performance
of current designs can be ascertained, and several alternate designs
can be tested without physically fabricating them in the early
design phases and without initially extensive and costly experi-
mentation. Subsequently, the characterization techniques
described earlier in Section 4 may be employed in a potentially
more resourceful manner towards optimizing processes and
systems.
Molecular dynamics simulations have been used to predict the
influence of plasticizers, like glycerol, on Tg, even for hydrophilic
polymers like starch [252]. In addition, the Tg of materials systems
comprising ibuprofen or theophylline in Eudragit has been pre-
dicted by Maus et al. [253] (Fig. 7). The Tg of a polymer is expected
to have a considerable influence on the choice of printing temper-Fig. 7. Plot of the computed specific volume (v) versus temperature (T) for
ibuprofen in Eudragit. The intersection between the two lines, resulting from a
linear regression of the data points, corresponds to the glassy and rubbery states
determined by the simulated Tg values. Figure reproduced with permission [253].
20atures for AM technologies based on melting and sintering, for
example, FDM and SLS. Such insights from molecular dynamics
simulations are therefore invaluable for process and material opti-
mization. Beyond its uses in manufacturing by AM, such simula-
tions also facilitate rapid prototyping in early design and
development phases. Alternative types of simulations are also
available for these purposes.
Yuan et al. have developed numerical simulations, which con-
sider printing speed, thermal convection coefficient, nozzle diame-
ter, and latent heat of crystallisation, to predict evolution of
crystallization of polymers by a simulation method known as the
finite element method [254]. This approach is particularly critical
to understand the interplay between polymer and process for pre-
venting unwanted crystallization of the drug and/or polymer for
product performance and/or printability.
In addition to simulations, a second example of the potential
manifestation of digitalization in the evolving pharmaceutical
AM landscape is that of digital twins. A digital twin is defined as
‘‘a set of virtual information constructs that fully describes a poten-
tial or actual physical manufactured product from the micro
atomic level to the macro geometrical level” [255]. A digital twin
consists of three basic components, namely, a physical component,
a virtual component, and automated data communications that
integrate these components. Digital twins have various potential
applications in pharmaceutical AM, including but not limited to,
understanding the roles of various process parameters, under-
standing the sensitivity of product quality to process variations,
prediction of productivity, material tracking, and quality assurance
[256]. For polymers in AM, a potential benefit foreseen in this
review stems from the variety of AM processes and their utilization
of different classes of polymers to ensure printability. Here, digital
twins could guide polymer selection for a wide variety of AM tech-
nologies such that the optimal polymers and grades are selected
not only for printability but also for product performance. In addi-
tion, since geometric design freedom is touted as one of the princi-
pal advantages of AM, digital twins may have a high potential for
geometry assurance of printed products and for evaluating the
contribution of varying inputs such as polymers with different
physicochemical properties to enhanced geometric flexibility and
accuracy.
Importantly, digital twins are still in their first generation and
yet to be implemented into pharmaceutical AM. In the meantime,
the reader is referred to two recent reviews, the first by Chen et al.
[256] on digital twins in biopharmaceutical manufacturing, which
explores generalized applications without a specific mention of AM
and the second by Zhang et al. [257] on digital twins in additive
manufacturing in several industries but not pharma. Taken
together, these recent reviews allude to a potential opportunity
noted in this review that is yet to be explored, that is, digital twins
in pharmaceutical additive manufacturing and more specifically,
digital twins to guide the selection and utilization of a wider vari-
ety of approved polymers in pharmaceutical additive
manufacturing.
Yet another emerging trend in pharmaceutical AM is artificial
intelligence, particularly machine learning [251]. A few examples
will be outlined in this paragraph. Elbadawi et al. used machine
learning to predict the drug release rate from FDM-printed PCL
units based on melt rheology data (i.e., shear and complex viscosity
as a function of shear rate and oscillation frequency, respectively,
at different temperatures). Three different machine learning tech-
niques, namely, multi-linear regression, decision trees, and support
vector machines, were used in this study [139]. Whilst this study
used a small training set of eight formulations and tested the
machine learning methods on data from one formulation, in
another study, Elbadawi et al. used data from 614 drug-loaded for-
mulations to predict the selection of printing temperature based
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k-nearest neighbours, support vector machines, random forests,
neural networks, and deep learning) [189]. M3DISEEN is a web
application that was developed based on the used machine learn-
ing techniques to, for example, predict process temperatures for
melt extrusion and printing of drug-polymer formulations [189].
The data inputs to M3DISEEN were based on 145 different materi-
als. Interestingly, the random forest machine learning method
reveals that the choice of polymer has a larger influence on the
melt extrusion temperature, filament mechanical characteristics,
and printability, than plasticizers, lubricants, drugs, disintegrants,
surfactants, and so forth. However, the choice of added lubricant
and plasticizer were shown to have somewhat higher influence
on the printing temperatures than the choice of polymer [189].
With these early adaptations of artificial intelligence in pharma-
ceutical AM, expanding opportunities towards the improved use
of rheological information to predict both drug release rates and
printing performance by machine learning, for example, is possibly
not far away. Further examples can be found in the review [251].4.9. Choosing the right techniques for the right purpose
This section has explored the variety of characterization tech-
niques that are currently available to assess properties of the raw
materials or intermediates to ensure printability with selected
AM processes and/or to optimize product performance and/or to
monitor the printing process. As illustrated in Fig. 8, the same tech-
niques may be useful for several of these purposes. The current
prevalence of different characterization techniques in AM litera-
ture is expected to be biased by the relative use of each AM tech-
nique in pharmaceutical research. Relative use may, in turn,
depend on ease of access to various instruments, cost barriers,
and so forth. Consequently, the higher prevalence of one technique
over another cannot be used as a direct proxy for their relative
suitability or usefulness of each characterization technique.Fig. 8. Overview exemplifying the diversity of techniques used for characterization of fee
across AM of pharmaceutical oral products.
21This review has revealed several emerging techniques with
respect to adoption in AM, such as more powerful X-ray techniques
like X-ray mCT, SAXS and WAXS, and highly specialized techniques,
such as ToF-SIMS and Terahertz pulsed imaging, which are still
underutilized and should be further explored for their benefits in
pharmaceutical AM. The incorporation of advanced computational
methods and digital tools for improved printability and product
performance could contribute to improved understanding of the
interplay between these functions and could potentially broaden
the range of polymers and applications of polymers in pharmaceu-
tical AM.5. Conclusion
At the beginning of this review, three key questions were posed,
which this review has begun to answer. Firstly, regarding the
extent of utilisation of pharmaceutically approved polymers across
various AM technologies, i.e., which polymers are not yet used and
why?
Although this review revealed that more than 30 pharmaceuti-
cally approved polymers are currently used in various AM tech-
niques, some are used more frequently than others. Interestingly,
polymers that have widespread use in a given AM technique, lack
use in other AM techniques based on similar polymer transforma-
tion principles e.g. melting. Several polysaccharides, cellulose
derivatives, and polymer-based surfactants have been highlighted
in this review for their potential in specific AM technologies. Cur-
rently, AM in biomedical, food, and confectionary industries pro-
vide a good indication of which pharmaceutically approved
polymers could be adopted into pharmaceutical AM for oral drug
delivery in future. A driving force for exploring today’s underuti-
lized polymers is the emergence of new pharmaceutical chal-
lenges, e.g. delivery of biological drugs, where the need for
combining diverse polymers with innovative AM platforms may
become even more critical in contributing to the effectiveness of
the next generation of pharmaceutical products.dstock or process input, in-process monitoring, and end-products or process output
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evant to different stages of the AM process, e.g. feeding, deposition,
and adhesion, compare across the various AM technologies used in
pharmaceutical research? This review revealed that required poly-
mer properties for successful feeding, deposition, and adhesion
were similar across the various melt-based techniques (FDM, SLS
and melt-DoD) and across the various solvent-based techniques
(PAM, solvent-based DoD and DoP). The most important polymer
properties for melt-based AM are thermal properties and melt rhe-
ology. For solvent-based AM, rheology and surface tension of print-
ing inks are critical. In addition, based on the feedstock form,
polymer properties that are crucial include mechanical properties
(for FDM filament feedstocks), viscosity (for solution or molten
feedstocks), and powder flow (for powder-based feedstocks).
The last question posed involved addressing whether the char-
acterization techniques already used to assess product perfor-
mance are equally suited to assess printability. Indeed, this
review has highlighted that most of the characterization tech-
niques already used to assess product performance are equally
suitable for assessing material suitability for printability. Looking
to the future, further opportunities like enhanced use of PAT tools,
in silico techniques, and even certain infrequently used characteri-
zation methods like advanced scattering techniques or specialized
techniques like TOF-SIMS and terahertz spectroscopy, show poten-
tial in not only clarifying the role of polymers for AM but achieving
this much-needed balance between printability and product per-
formance across AM technologies with existing pharmaceutical
polymers.
By demonstrating and discussing trade-offs between printabil-
ity and product performance through simple case examples,
including achieving and stabilizing the solid state and facilitating
drug delivery applications, this review has shed a light on the inad-
equate exploration of printability versus product performance
trade-offs which are anticipated for future bridging of proof-of-
concept demonstrations to mainstream realization of pharmaceu-
tical AM. This knowledge gap is crucial to address in order to opti-
mally balance printability and product performance and harness
the full potential of pharmaceutical AM.6. Expert opinion
Materials (e.g. polymers) and manufacturing processes (e.g.
AM) share a common purpose of enabling the pharmaceutical pro-
duct to perform as intended. For them to carry out this purpose,
compatibility between polymers and AM processes to allow print-
ability is one crucial aspect. This review revealed that there is no
shortage of pharmaceutically approved polymers, designed to elicit
a variety of product performance attributes. Despite the wide
range of available polymers, the current material diversity of each
AM process appears to be quite restricted by their different work-
ing principles. Interestingly, by approaching this review from an
overarching perspective of whether AM technologies are melt-
based or solvent-based processes, whether they use continuous
extrusion or jetting, whether they require pre-processing of feed-
stocks or not, and so forth, we have learned that distinct working
principles do not necessarily imply a distinct set of appropriate
polymers for each process. On the contrary, by assessing polymer
suitability based on required properties during feeding, deposition,
and adhesion stages of printing, several underutilized but suitable
polymers for the desired product performance and for printability
have become evident. However, an added complication to fully
harnessing available polymers in AM is the trade-offs between
printability and product performance that exist but are, surpris-
ingly, given limited attention in progressing this field. Until all
encountered trade-offs between product performance and print-22ability are solved, selecting polymers (and entire materials sys-
tems) for optimal product performance to suit patient needs will
always be a priority over printability. This runs the risk of avoid-
ance of AM implementation in favour of alternative manufacturing
approaches. The consequence is that the unique advantages of AM
for complex, personalized products and advanced drug delivery
applications, may not progress from proof-of-concept to wide-
spread adoption. When faced with a choice between introducing
new materials to suit the current state of AM printers or develop-
ing printers to suit the current scope of pharmaceutically approved
polymers, we strongly favour the latter. From an industrial per-
spective, introduction of new excipients, including polymers, is
typically a time- and cost-intensive endeavour. Moreover, AM is
in the midst of a rapid and ongoing technological evolution, which
is equipped to maximize compatibility between emerging AM
printing and a broader range of polymers than are currently used.
We anticipate that, in future, high performing multifunctional or
hybrid printers that combine several AM processes with different
working principles will play a key role in expanding material diver-
sity and enabling industrial applicability and adoption in the phar-
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